Agilon Health (AGL) Net Equity Issued and Repurchased (2020 - 2025)

Agilon Health (AGL) has 6 years of Net Equity Issued and Repurchased data on file, last reported at -$161000.0 in Q1 2025.

• Quarterly Net Equity Issued and Repurchased fell 108.9% year-over-year to -$161000.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was -$803000.0 (down 119.65% YoY) and the FY2025 annual result came in at -$3.0 million, down 356.56% from the prior year.
• Net Equity Issued and Repurchased slipped to -$161000.0 in Q1 2025, from -$22000.0 in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $16.5 million in Q4 2021 to a low of -$787000.0 in Q2 2023.
• A 5-year average of $4.2 million and a median of $1.8 million in 2024 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2021 — Net Equity Issued and Repurchased soared 1924.57% — and 2023, when it plunged 114.16%.
• Tracing AGL's Net Equity Issued and Repurchased over 5 years: stood at $16.5 million in 2021, then plunged by 85.56% to $2.4 million in 2022, then tumbled by 82.98% to $405000.0 in 2023, then sank by 105.43% to -$22000.0 in 2024, then tumbled by 631.82% to -$161000.0 in 2025.
• The last three Net Equity Issued and Repurchased figures came in at -$161000.0 (Q1 2025), -$22000.0 (Q4 2024), and -$156000.0 (Q3 2024), per Business Quant data.